{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vedolizumab+SC", "query": { "intervention": "Vedolizumab SC" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 15, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vedolizumab+SC&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-05T04:50:38.637Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06581328", "title": "A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Ulcerative Colitis", "Crohn's Disease" ], "interventions": [ { "name": "Vedolizumab IV", "type": "DRUG" }, { "name": "Vedolizumab SC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 400, "start_date": "2025-03-27", "completion_date": "2028-06-01", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-09-05T04:50:38.637Z", "location_count": 101, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 89 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06581328" }, { "nct_id": "NCT06405087", "title": "A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis", "Crohn's Disease" ], "interventions": [ { "name": "Vedolizumab SC", "type": "DRUG" }, { "name": "No Intervention", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 70, "start_date": "2025-10-27", "completion_date": "2030-08-12", "has_results": false, "last_update_posted_date": "2026-06-22", "last_synced_at": "2026-09-05T04:50:38.637Z", "location_count": 14, "location_summary": "Phoenix, Arizona • Loma Linda, California • Orange, California + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Loma Linda", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Park Ridge", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06405087" }, { "nct_id": "NCT03948581", "title": "A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Needle Safety Device (PFS+NSD) in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Vedolizumab SC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 102, "start_date": "2018-02-21", "completion_date": "2018-09-21", "has_results": true, "last_update_posted_date": "2022-07-29", "last_synced_at": "2026-09-05T04:50:38.637Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03948581" }, { "nct_id": "NCT03961308", "title": "A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Vedolizumab SC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 204, "start_date": "2018-03-12", "completion_date": "2018-11-21", "has_results": true, "last_update_posted_date": "2019-11-14", "last_synced_at": "2026-09-05T04:50:38.637Z", "location_count": 2, "location_summary": "Tempe, Arizona • Lincoln, Nebraska", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03961308" }, { "nct_id": "NCT06880744", "title": "A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "Risankizumab", "type": "DRUG" }, { "name": "Vedolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 573, "start_date": "2025-06-17", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-08-04", "last_synced_at": "2026-09-05T04:50:38.637Z", "location_count": 74, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 65 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06880744" }, { "nct_id": "NCT02497469", "title": "An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colitis, Ulcerative" ], "interventions": [ { "name": "Vedolizumab", "type": "DRUG" }, { "name": "Adalimumab placebo", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Vedolizumab placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 771, "start_date": "2015-06-29", "completion_date": "2019-01-18", "has_results": true, "last_update_posted_date": "2020-01-28", "last_synced_at": "2026-09-05T04:50:38.637Z", "location_count": 77, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 70 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02497469" }, { "nct_id": "NCT06045754", "title": "A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Crohn's Disease" ], "interventions": [ { "name": "Vedolizumab", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Ustekinumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 50, "start_date": "2024-04-18", "completion_date": "2027-06-28", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-09-05T04:50:38.637Z", "location_count": 41, "location_summary": "Dothan, Alabama • Sun City, Arizona • La Jolla, California + 37 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Sun City", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06045754" }, { "nct_id": "NCT02611817", "title": "Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Crohn's Disease" ], "interventions": [ { "name": "Vedolizumab SC 108 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Vedolizumab IV 300 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 644, "start_date": "2016-01-04", "completion_date": "2019-08-06", "has_results": true, "last_update_posted_date": "2022-05-25", "last_synced_at": "2026-09-05T04:50:38.637Z", "location_count": 30, "location_summary": "Phoenix, Arizona • Hamden, Connecticut • Middletown, Connecticut + 27 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Hamden", "state": "Connecticut" }, { "city": "Middletown", "state": "Connecticut" }, { "city": "Inverness", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02611817" }, { "nct_id": "NCT06100289", "title": "A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis", "Crohn's Disease" ], "interventions": [ { "name": "Vedolizumab IV", "type": "DRUG" }, { "name": "Vedolizumab SC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 70, "start_date": "2025-01-22", "completion_date": "2028-05-16", "has_results": false, "last_update_posted_date": "2026-08-03", "last_synced_at": "2026-09-05T04:50:38.637Z", "location_count": 14, "location_summary": "Phoenix, Arizona • Loma Linda, California • Orange, California + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Loma Linda", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Park Ridge", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06100289" }, { "nct_id": "NCT03961295", "title": "A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Vedolizumab SC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 24, "start_date": "2018-02-22", "completion_date": "2018-08-28", "has_results": true, "last_update_posted_date": "2019-11-13", "last_synced_at": "2026-09-05T04:50:38.637Z", "location_count": 1, "location_summary": "Lincoln, Nebraska", "locations": [ { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03961295" } ] }